Register to receive a free US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery report synopsis and brochure
Ascensia Diabetes Care Announces Commercial Agreement with Dexcom, Inc. to Include CONTOUR®NEXT ONE BGMS with the Dexcom G5® Continuous Glucose Monitoring System for Patients Covered by Medicare
Ascensia Diabetes Care recently announced it has entered into an agreement with DexCom, Inc., a leader in continuous glucose monitoring (CGM) technology, to provide the Ascensia CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) as part of the Dexcom G5® CGM System Medicare offering.
The complete bundle will be available to people with diabetes who are covered by Medicare and qualify for therapeutic CGM. Dexcom G5® is currently the only CGM system approved by the FDA to meet the criteria for therapeutic CGM.
Under the terms of the agreement, Ascensia Diabetes Care’s CONTOUR®NEXT ONE BGMS will be provided to eligible people with diabetes in the bundle of supplies for the Dexcom G5® CGM System. The role of the CONTOUR®NEXT ONE BGMS will be to provide highly accurate readings for CGM calibration.
Michael Kloss, CEO of Ascensia Diabetes Care, explained: “Continuous glucose monitoring is a rapidly growing technology, and Dexcom holds world class expertise in the development and delivery of CGM systems. We are delighted to partner with Dexcom to help this group of patients with their diabetes management, by providing them with our highly accurate CONTOUR®NEXT ONE BGMS as part of the bundle they receive.”
Robert Schumm, VP and Managing Director of Ascensia Diabetes Care US Inc., said: “For those people with diabetes who are eligible to receive the G5 through Medicare, Ascensia is thrilled to become the partner of choice for calibration of the Dexcom G5® CGM System. We believe this combination will help improve diabetes management for people on Medicare who are eligible for therapeutic CGM.”
The Dexcom G5® CGM System provides dynamic glucose information by showing a user his or her glucose level, along with both trend and rate of change information. People who use the G5® CGM System calibrate regularly to verify the CGM sensor reading is on track.
Rick Doubleday, Chief Commercial Officer, Dexcom, said: “Dexcom is at the forefront of diabetes technology, and in Ascensia, we saw a business partner that matches our own commitment to best-in-class products and services for people with diabetes. With this agreement, we are pleased to begin offering a complete bundle to Medicare-eligible patients, enabling access to the Dexcom G5 CGM System as efficiently as possible.”
The Ascensia CONTOUR®NEXT ONE system when used by itself has been shown to deliver remarkable accuracy, with 95% of results within ±8.4 mg/dL or ±8.4% of the laboratory reference values for glucose concentrations < 100 mg/dL or ≥ 100 mg/dL, respectively in the hands of patients.
Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies
Abbott and Bigfoot Biomedical recently announced that the companies have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott’s FreeStyle® Libre glucose sensing technology with Bigfoot’s insulin delivery solutions in the United States.
This collaboration brings people living with diabetes a significant step closer to the ultimate goal of eliminating much of the daily burden of diabetes management. As part of the agreement, Abbott will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology. Bigfoot will utilize this technology in the development of the first-ever personalized, user-friendly systems intended to optimize insulin delivery without the need for fingerstick calibration of a glucose sensor.
“Diabetes is increasing at record rates globally. There is a significant demand for tools that are intuitive and easy to use to help people take control of this complicated, challenging condition, but innovation in this area has been slow,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “Together with Bigfoot, we are challenging conventional methods of diabetes management by bringing together our expertise in superior glucose monitoring technology with a best-in-class insulin delivery system that is designed with the patient in mind. This will fundamentally transform the way diabetes is managed.”
All people with Type 1 diabetes, and nearly one third of people with Type 2 diabetes, must inject insulin to manage their glucose – that’s more than 6 million people in the U.S. alone. Bigfoot and Abbott both share a vision to simplify the use of diabetes management systems for these insulin users: a goal that moves beyond technology and into accessibility and cost reduction for individuals, their health care providers and payers.
“Bigfoot is committed to solving the hard problems inherent in blending consumer technology, enterprise systems and Class III medical devices in an effort to design an easy-to-use system for people with diabetes,” said Jeffrey Brewer, Bigfoot Biomedical president and chief executive officer. “Both Abbott and Bigfoot understand the real-world use of diabetes devices. A no-calibration glucose sensor is the final piece of the puzzle needed to enable consumer-friendly and accessible integrated insulin delivery systems.”
Bigfoot has both injection and infusion pump-based insulin delivery systems in development. These investigational systems utilize intuitive design, Internet of Things connectivity, smartphone technology and machine learning automation to adjust insulin delivery or dosing with the intent to keep glucose levels in an optimal range. Bigfoot anticipates initiating a pivotal trial incorporating FreeStyle Libre technology in 2018 at clinical research sites across the United States.
Abbott’s FreeStyle Libre system was introduced across Europe in 2014, and is now available in more than 35 countries and used by more than 300,000 people with diabetes around the world. Two published clinical trials and real-world evidence from more than 50,000 users show that people who use the FreeStyle Libre system scan their glucose levels an average of at least 15 times per day. The studies show that people who scan more frequently spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels, demonstrating improved glucose control overall.
“Our companies have a shared commitment to developing products that are patient focused – simple, convenient, discreet, affordable and provide actionable information,” said Brewer. “We could not be more excited to be collaborating with Abbott’s outstanding team in bringing new innovations to people with diabetes.”
In the U.S., the FreeStyle Libre system is currently pending approval by the U.S. Food and Drug Administration.
For Further Information
More on the diabetes device market in the U.S. can be found in a series of reports published by iData Research entitled the US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery. The suite covers reports on the following markets: blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps.
The iData report series on diabetes devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about diabetes device market data or procedure data, register online or email us at info@idataresearch.net for a US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery brochure and synopsis.
